Tumor suppressor p53 regulates insulin receptor (INSR) gene expression via direct binding to the INSR promoter
Metrics: PDF 23 views | Full Text 69 views | ?
Rive Sarfstein1 and Haim Werner1,2
1 Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
2 Yoran Institute for Human Genome Research, Tel Aviv University, Tel Aviv 69978, Israel
Keywords: insulin; insulin-like growth factor-1 (IGF1); insulin receptor; IGF1 receptor; p53
Received: April 14, 2020 Accepted: June 01, 2020 Published: June 23, 2020
A significant volume of clinical and epidemiological data provides support to the concept that insulin and the insulin receptor (INSR) have an important role in breast cancer. Tumor suppressor p53 is the most frequently mutated molecule in human cancer. The present study was aimed at evaluating the hypothesis that p53 governs the expression and activation of the INSR gene in breast cancer cells. In addition, the study was designed to investigate the mechanism of action of p53 in the context of INSR gene regulation. The availability of MCF7 breast cancer-derived cell lines with specific disruption of either the insulin-like growth factor-1 receptor (IGF1R) or INSR allowed us to address the impact of the IGF1R and INSR pathways on p53 expression. Data indicate that the INSR gene constitutes a target for p53 action. Wild-type p53 stimulated INSR promoter activity in control cells while disruption of endogenous IGF1R or INSR led to inhibition of promoter activity by p53. Mutant p53 strongly stimulated INSR promoter. Furthermore, p53 directly binds to the INSR promoter in cells with a disrupted IGF1R. Combined, our results identified complex functional and physical interactions between p53 and the INSR pathway. The implications of the p53-INSR interplay in breast cancer needs to be further investigated.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.